Gastrointestinal Cancer News

A cell-free DNA multicancer early detection test demonstrated an ability to predict cancer and the tissue of origin in individuals with clinical suspicion of cancer, according to results of the Circulating Cell-free Genome Atlas study presented at the virtual American Association for Cancer Research Annual Meeting.

Individuals with cancer and COVID-19 infection appeared at higher risk for severe outcomes than cancer-free individuals with the novel coronavirus, according to results of a multicenter study presented at the virtual American Association for Cancer Research Annual Meeting.

COM701, a novel first-in-class immune checkpoint inhibitor, demonstrated antitumor activity alone and in combination with nivolumab among patients with advanced solid tumors, according to results of a phase 1 study presented at the virtual American Association for Cancer Research Annual Meeting.

The FDA granted priority review to the following therapies in development for oncology and hematology indications:

David A. Tuveson, MD, PhD, FAACR, has been chosen president-elect of American Association for Cancer Research for 2020-2021.

Proton beam therapy appeared to reduce the risk for and severity of adverse events compared with intensity-modulated radiation therapy for patients with locally advanced esophageal cancer, according to results of a randomized phase 2B study published in Journal of Clinical Oncology.

Colorectal cancer could have been diagnosed earlier or possibly prevented among adults aged 40 to 49 years had these individuals undergone screening in accordance with family history-based guidelines, according to results of a retrospective analysis published in Cancer.

The FDA granted accelerated approval to pemigatinib for treatment of certain adults with previously treated unresectable cholangiocarcinoma.

The American Cancer Society approved $36.1 million in funding for 79 research and training grants.

Novartis has reached an agreement with biopharmaceutical company TScan Therapeutics to develop new autologous T-cell receptor therapies for the treatment of solid tumors.